BioCardia Inc logo

BCDA - BioCardia Inc News Story

$4.2 0.2  4.7%

Last Trade - 13/04/21

Micro Cap
Market Cap £47.7m
Enterprise Value £32.1m
Revenue £106k
Position in Universe 5462nd / 6841

BioCardia Signs Agreement With Leading Japanese Pharmaceutical Company for Catheter Biotherapeutic Delivery Product Candidates

Tue 23rd February, 2021 1:00pm
For best results when printing this announcement, please click on link below:

SAN CARLOS, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- BioCardia(®), Inc.
( [Nasdaq:
BCDA], today announced that it has entered into an agreement with a leading
Japanese pharmaceutical company related to BioCardia Helix catheter
biotherapeutic delivery product candidates. Under the terms of the agreement,
BioCardia will receive a $500,000 up-front payment, a portion of which is
creditable for biotherapeutic delivery products and support services. The
agreement has a one-year term with an option to negotiate for a non-exclusive
world-wide license to BioCardia Helix catheter biotherapeutic delivery product
candidates for certain cell types for cardiac indications.

“Our collaboration with this leading Japanese pharmaceutical company further
validates our core Helix biotherapeutic delivery technology as the leading
delivery platform for local cell, gene and protein-based therapy to the heart.
To our knowledge, the Helix system is currently the only intra-myocardial
delivery system in clinical use worldwide. We are grateful for the additional
recognition of the Helix system’s potential to enable the successful
development of others’ therapies,” said BioCardia CEO Peter Altman, Ph.D.
“Recent publications have demonstrated our Helix delivery platform is the
most efficient(()(1)), and has the best clinical performance(()(2)()). These
Helix system advantages are believed to underlie our recently reported
CardiAMP™ cell therapy clinical results in heart failure ((3)). We look
forward to bringing all of our experience and delivery technologies to bear to
help advance this partner’s important therapeutic development efforts.”

BioCardia, Inc.
headquartered in San Carlos, California, is developing regenerative biologic
therapies to treat cardiovascular and respiratory disease. CardiAMP autologous
and Neurokinin-1 Receptor Positive allogenic cell therapies are the
Company’s biotherapeutic platforms in clinical development. The Company's
products include the Helix Biotherapeutic Delivery System and its steerable
guide and sheath catheter portfolio. BioCardia also partners with other
biotherapeutic companies to provide its Helix system and clinical support for
their programs studying therapies for the treatment of heart failure, chronic
myocardial ischemia, and acute myocardial infarction. For more information,

Forward Looking Statements:
This press release contains forward-looking statements that are subject to
risks and uncertainties. Forward-looking statements include statements
regarding our intentions, beliefs, projections, outlook, analyses or current

We may use terms such as “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should,” “approximately” or other words that
convey the uncertainty of future events or outcomes to identify these
forward-looking statements. These forward-looking statements reflect our view
as of the time such statement is made and are not guarantees of future
performance or developments. Actual results and events may differ materially
from information contained in the forward-looking statements. BioCardia
expressly disclaims any intent or obligation to update these forward-looking
statements, except as required by law.
1. Mitsutake Y, Pyun WB, Rouy D, et al. Improvement of local cell delivery
using Helix transendocardial delivery catheter in a porcine heart. Int Heart
J. (2017). 
2. Raval AN, Pepine CJ. Clinical safety profile of transendocardial catheter
injection systems: A plea for uniform reporting. Cardiovascular
Revascularization Medicine (2020).
3. Raval AN, Johnston PV, Duckers HJ, et al. Point of care, bone marrow
mononuclear cell therapy in ischemic heart failure patients personalized for
cell potency: 12-month feasibility results from CardiAMP heart failure roll-in
cohort, Int J. Cardiology (2020).
David McClung, Chief Financial Officer
(650) 226-0120

Michelle McAdam, Chronic Communications, Inc.
(310) 545-6654


GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.